Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
NCT ID: NCT01414920
Last Updated: 2016-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
368 participants
INTERVENTIONAL
2011-08-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
NCT01829464
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
NCT01834274
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
NCT01549964
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
NCT00760344
Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
NCT00762112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4) approved as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.
This study will investigate the effects of the combination of TAK-875 with a DDP-4 inhibitor on glycosylated hemoglobin reduction.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo QD
Placebo
TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
TAK-875 25 mg QD
TAK-875
TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
TAK-875 50 mg QD
TAK-875
TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
Sitagliptin 100 mg QD
Sitagliptin
Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
TAK-875 25 mg QD + Sitagliptin 100 mg QD
TAK-875 and Sitagliptin
TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
TAK-875 50 mg QD + Sitagliptin 100 mg QD
TAK-875 and Sitagliptin
TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
TAK-875
TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
TAK-875
TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
Sitagliptin
Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
TAK-875 and Sitagliptin
TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
TAK-875 and Sitagliptin
TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
3. The participant has either:
* A historical diagnosis of Type 2 Diabetes (T2DM) without the chronic use (defined as \>7 days) of anti-diabetic therapy within 8 weeks prior to Screening, and with at least an 8-week documented history of a diet and exercise plan at Screening OR,
* A historical diagnosis of T2DM and stable on at least 1500 mg per day (or maximum tolerated dose) of metformin as monotherapy for at least 8 weeks at Screening. Participants on a stable dose of metformin who enter the study will continue on the same dose of metformin throughout the duration of the study.
4. The participant is a man or woman and aged 18 to 80 years, inclusive.
5. The participant's body mass index (BMI) (kg/m2) at Screening is ≥23 and ≤45.
6. The participant has an glycosylated hemoglobin (HbA1c) level at Screening between 7.5% and 10.0%, inclusive, if on metformin and between 7.5% to 10.9%, inclusive, if treated with diet and exercise alone.
7. The participant has a fasting plasma glucose level \<14.4 mmol/L (\<260 mg/dL), at Screening.
8. The participant has a fasting C-peptide concentration ≥0.26 nmol/L (≥0.8 ng/mL) at Screening.
9. If the participant takes any chronic, non-excluded medications, the dose of these medications must have been stable (no change in dose or drug) for at least 4 weeks prior to Screening.
10. The participant is able and willing to monitor their glucose levels with a home glucose monitor and consistently record his or her own blood glucose concentrations according to the given instructions.
11. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.
12. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
13. A female participant of childbearing potential must have a negative serum human chorionic gonadotropin (HCG) pregnancy test at Screening (Visit 1) and at Placebo Run-in (Visit 2). A negative urine HCG pregnancy test is also required at Randomization (Visit 3), prior to administration of the first dose of double-blind study medication.
14. The participant's compliance with single-blind study medication during the run-in phase is at least 80% and does not exceed 120% based on tablet counts performed by the study staff.
Exclusion Criteria
2. The participant has been enrolled in a previous TAK-875 study.
3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
4. The participant has a history of hypersensitivity or allergies to TAK-875 or sitagliptin, or their excipients.
5. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the Screening visit.
6. The participant has a history of cancer that has been in remission for \<5 years prior to Screening (a history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is allowed).
7. The participant has systolic blood pressure ≥150 mm Hg or diastolic pressure ≥90 mm Hg at Screening (Visit 1) or Baseline (Visit 3) (as confirmed by repeat measurement 30 minutes after initial measurement).
8. The participant has a creatine phosphokinase (CPK) level ≥5x the upper limit of normal (ULN) at Screening.
9. The participant has a hemoglobin level of ≤12 g/dL (120 gm/L) for men and ≤10 g/dL (100 gm/L) for women at Screening.
10. The participant has ALT and/or AST levels ≥2.5x ULN at Screening.
11. The participant has a total bilirubin level \> ULN at Screening.
12. The participant has a serum triglyceride concentration ≥4.5 mmol/L (≥400 mg/dL) at Screening.
13. The participant has an estimated glomerular filtration rate ≤60mL/min using the Modification of Diet in Renal Disease (MDRD) equation at Screening.
14. The participant has a documented history or concurrent signs of uncontrolled (not euthyroid) thyroid disease (eg, autoimmune thyroid diseases such as Graves disease and Hashimoto thyroiditis or active thyroid nodules).
15. The participant has a history of pancreatitis.
16. The participant has a history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
17. The participant has a history of gastric bypass surgery or has diabetic gastroparesis that in the investigator's opinion is moderate or severe and hence may impair absorption of study medication.
18. The participant has had coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, unstable angina pectoris, clinically significant abnormal electrocardiogram (ECG), cerebrovascular accident or transient ischemic attack within 6 months prior or at Screening.
19. The participant has a history of any hemoglobinopathy that may affect determination of HbA1c.
20. The participant has a positive test result for hepatitis B surface antigen and antibody to hepatitis C virus, and/or has known history of human immunodeficiency virus at Screening.
21. The participant has donated or received any blood products within 12 weeks prior to Screening.
22. The participant received medication prior to Screening as listed in the excluded Medications section.
23. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate an ova during such time period.
24. If male, the participant intends to donate sperm during the course of this study or for 30 days thereafter.
25. The participant has any other physical or psychiatric disease or condition that in the judgment of the investigator may affect life expectancy or may make it difficult to successfully manage and follow the participant according to the protocol.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sr. Medical Director Clinical Science
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Brimingham, Alabama, United States
Chandler, Arizona, United States
Glendale, Arizona, United States
Green Valley, Arizona, United States
Mesa, Arizona, United States
Tempe, Arizona, United States
Tucson, Arizona, United States
Buena Park, California, United States
Irvine, California, United States
Norwalk, California, United States
Paramount, California, United States
Rancho Cucamonga, California, United States
San Ramon, California, United States
Spring Valley, California, United States
Vista, California, United States
Walnut Creek, California, United States
Westlake Village, California, United States
Colorado Springs, Colorado, United States
Lakewood, Colorado, United States
Brandon, Florida, United States
Clearwater, Florida, United States
DeLand, Florida, United States
Hallandale, Florida, United States
Hialeah, Florida, United States
Jupiter, Florida, United States
Longwood, Florida, United States
Miami, Florida, United States
Miami Lakes, Florida, United States
Orlando, Florida, United States
Pembroke Pines, Florida, United States
St. Petersburg, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Roswell, Georgia, United States
Suwanee, Georgia, United States
Boise, Idaho, United States
Chicago, Illinois, United States
Valparaiso, Indiana, United States
Crestview Hills, Kentucky, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
Bangor, Maine, United States
Elkridge, Maryland, United States
Brockton, Massachusetts, United States
Chelsea, Michigan, United States
Kalamazoo, Michigan, United States
Olive Branch, Mississippi, United States
Berlin, New Jersey, United States
Margate City, New Jersey, United States
Toms River, New Jersey, United States
Brooklyn, New York, United States
Buffalo, New York, United States
Calabash, North Carolina, United States
Fuquay-Varina, North Carolina, United States
Morehead City, North Carolina, United States
Winston-Salem, North Carolina, United States
Akron, Ohio, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Lyndhurst, Ohio, United States
Marion, Ohio, United States
Willoughby Hills, Ohio, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
Broomall, Pennsylvania, United States
Feasterville, Pennsylvania, United States
Fleetwood, Pennsylvania, United States
Cranston, Rhode Island, United States
Chattanooga, Tennessee, United States
Crossville, Tennessee, United States
Kingsport, Tennessee, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Irving, Texas, United States
North Richland Hills, Texas, United States
Pearland, Texas, United States
San Antonio, Texas, United States
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1115-5044
Identifier Type: REGISTRY
Identifier Source: secondary_id
TAK-875_202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.